PCN163 Cost-Effectiveness of Ipilimumab in Previously Untreated Patients for Advanced Melanoma in Sweden  by Barzey, V. et al.
A642  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
(comparison cohort) who were the same age, race, and gender were identified and 
matched. A random index date was chosen to minimize selection bias. Patients in 
both cohorts were required to be at least age 18 years, with continuous medical and 
pharmacy benefits 1-year pre- and 1-year post-index date. One-to-one propensity 
score matching (PSM) was used to compare health care costs and utilizations during 
the follow-up period, between the diseased and comparison cohorts, and adjusted 
for baseline demographic and clinical characteristics. Results: After risk adjust-
ment by PSM, a total of 19,079 patients in each cohort were matched. Significantly 
more breast cancer patients had inpatient admissions (23.77% vs. 12.56%, p< 0.0001) 
and long-term care (7.77% vs. 6.60%, p< 0.0001), other service (99.88% vs. 87.86%, 
p< 0.0001) and pharmacy visits (77.80% vs. 68.85%, p< 0.0001), compared to those 
without breast cancer. Breast cancer patients also incurred significantly higher 
inpatient ($2,141 vs. $1,537, p< 0.0001), long-term care ($7,471 vs. $5,335, p< 0.0001), 
other service visit ($23,592 vs. $14,780, p< 0.0001) and pharmacy costs ($3,379 vs. 
$2,787, p< 0.0001) compared to those in the comparison cohort. ConClusions: 
Breast cancer patients in the Medicaid program incurred substantially higher health 
care resource utilization and costs compared to those without the disease.
PCN161
Nab-PaClitaxel or DoCetaxel as alterNatives to solveNt-baseD 
PaClitaxel iN MetastatiC breast CaNCer (MbC): a Cost Utility 
aNalysis froM a ChiNese health Care PersPeCtive
Dranitsaris G.1, Yu B.2, Qing Z.2, King J.3, Zhang A.3, Kaura S.3
1Augmentium Pharma Consulting, Toronto, ON, Canada, 2Fudan University Shanghai Cancer 
Center, Shanghai, China, 3Celgene Corporation, Summit, NJ, USA
objeCtives: Paclitaxel and docetaxel are used for the treatment of MBC in China. 
However, one important drawback, particularly with docetaxel, is the potential for 
dose-limiting toxicity. To improve the side effect profile and efficacy of paclitaxel, 
an albumin-bound formulation (nab-paclitaxel) is currently available in China 
(Abraxane®). Clinical trials have demonstrated that nab-paclitaxel is safer and more 
effective than both docetaxel and paclitaxel. To provide economic data for China, 
a cost utility analysis comparing nab-paclitaxel to docetaxel, both as alternatives 
to paclitaxel was conducted. Methods: Clinical data was obtained from a meta 
analysis of randomized trials comparing either nab-paclitaxel (260 mg/m2 q3wk) 
or branded docetaxel (100 mg/m2 q3wk) to solvent-based branded paclitaxel (175 
mg/m2 q3wk). Health care resource use for the delivery of chemotherapy and the 
management of grade 3/4 toxicity was collected from a time and motion study 
in three Chinese cancer centers and from a survey of clinicians. Using the Time 
Trade-off technique, treatment preferences and utility estimates were obtained 
from interviewing 28 cancer patients from two centres in China. All costs were 
reported in 2014 $U. S. Results: Nab-paclitaxel had the most favourable safety 
profile characterized with the lowest incidence of grade 3/4 neutropenia, febrile 
neutropenia, anemia and stomatitis. This translated into lower costs for managing 
the grade 3/4 side effects of nab-paclitaxel relative to both docetaxel and paclitaxel 
($21 vs. $166 vs. $81). In the preference assessment, 22 of 28 (78.6%) patients selected 
nab-paclitaxel as their preferred agent. As an alternative to paclitaxel, the cost per 
quality adjusted life year (QALY) gained was more favourable with nab-paclitaxel 
than docetaxel ($57,900 vs. $130,600 respectively). ConClusions: Nab-paclitaxel is 
an economically attractive alternative to paclitaxel and docetaxel in MBC, providing 
a substantially lower cost per QALY. Additionally in the patient preference survey, 
78.6% of patients selected nab-paclitaxel as their preferred agent.
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objeCtives: Targeted therapy with ALK inhibitor crizotinib offers significant 
improvement in clinical outcome for treatment of EML4–ALK fusion positive non-
small cell lung cancer (NSCLC) patients. We estimated the cost-effectiveness of 
companion EML4-ALK genetic testing in combination with crizotinib treatment in 
the second-line setting for advanced NSCLC in Ontario. Methods: We performed 
a cost-effectiveness analysis using a Markov model from a Ministry of Health per-
spective and a lifetime horizon. Transition probabilities and mortality rates were 
calculated based on the data of a recent second-line randomized trial of crizotinib 
versus chemotherapy (Shaw et al. New Engl J Med 2013). Costs were obtained from 
OCCI database, public labs and Princess Margaret Hospital. All parameters were 
varied separately in one-way and selected two-way sensitivity analyses. Various 
scenarios to assess the impact of model assumptions about testing and treatment 
were conducted. Results:  The use of pemetrexed and docetaxel in ALK-rearranged 
NSCLC, based on our preliminary model, could yield as much as 0.539 QALY and 
0.429 QALY respectively, assuming no crossover from chemotherapy to crizotinib. 
Average costs per patient based on the preliminary model are estimated at CAD 
$19,388 for pemetrexed and $$33,226for docetaxel, with incremental cost-effective-
ness ratios of $333,595/QALY and $125,812/QALY gained respectively. The results of 
the one-way sensitivity analysis indicated that the primary drivers of the ICER were 
the utilities and cost of crizotinib treatment. The model was least sensitive to IHC 
and FISH genetic test costs, re-biopsy cost, probability of progression while on pem-
etrexed treatment and probability of re-biopsy. ConClusions: EML4–ALK genetic 
testing in combination with crizotinib treatment for all NSCLC patients eligible for 
chemotherapy is not economically attractive in the current setting. Lower drug costs 
would be required to make this strategy economically feasible.
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incremental quality-adjusted life years (QALYs) while ESAs were administered 
and during a Hb “normalisation period” following cancer treatment. Incremental 
long-term QALYs were accrued solely through extrapolated overall survival. Short-
term mortality and HRQoL associated with adverse events and RBCTs were not 
modelled. Costs included: ESA acquisition (list prices, British National Formulary) 
and administration, RBCT, additional blood tests with ESA therapy, and adverse 
event costs. Results: All ESAs except epoetin beta and darbepoetin alfa were 
cost-effective versus using RBCT only at an upper cost-effectiveness threshold of 
£30,000/QALY. Incremental cost-effectiveness ratios (ICERs) ranged from £19,400/
QALY (biosimilar epoetin alfa) to £35,000/QALY (epoetin beta). Probabilistic sensi-
tivity analysis showed that biosimilar epoetin alfa was cost-effective at the lower 
cost-effectiveness threshold of £20,000/QALY in 50.9% of simulations. In 19.5% of 
simulations it was clinically effective but not cost-effective and in 31.4% of simula-
tions it was dominated by RBCT only. Additional sensitivity analyses demonstrated 
that overall survival was one of the most influential and uncertain parameters. 
When the survival advantage of ESAs (not statistically significant) was removed, the 
ICERs for all ESAs were over £100,000/QALY. ConClusions:  There is substantial 
uncertainty regarding the impact of ESA therapy on overall survival, which leads to 
significant uncertainty about the cost-effectiveness of ESAs in CIA.
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objeCtives: To demonstrate the impact of QALY weightings based on the burden-of-
illness (BoI) of pancreatic cancer on the incremental cost-effectiveness ratio (ICER) of 
nab-paclitaxel plus gemcitabine (NPG) versus gemcitabine (G). Methods: A markov 
model using data from the MPACT trial plus resource use data and costs from NHS 
Scotland have been submitted to the Scottish Medicines Consortium. The base case 
ICER was £52,885/QALY based on a cost of £8,232 and a QALY gain of 0.156 (SMC DAD). 
QALY weightings up to a maximum of 2.5 distributed across six modifier factors, 
including BoI, have been proposed (NICE consultation on Value Based Assessment), 
with BoI measured according to proportional QALY shortfall associated with the con-
dition. The estimated 98% loss of healthy life (proportional QALY shortfall) in pan-
creatic cancer (Hutchings 2014) represents an almost complete loss of life, and thus 
a very high BoI. A BoI weighting of 2.5 (maximum weighting allocated entirely to BoI, 
or BoI FULL) and an alternative BoI weighting of 1.417 (maximum weighting shared 
equally between six modifiers, so 1/6thof 2.5, or BoI PARTIAL) were therefore applied to 
the QALY gain of NPG versus G. Results:  The BoI FULL weighting gives an adjusted 
QALY gain for NPG versus G of 0.39 and a corresponding ICER of £21,108/QALY. The 
BoI PARTIAL weighting gives an adjusted QALY gain for NPG versus G of 0.221 and 
a corresponding ICER of £37,249/QALY. ConClusions: Various ways of accounting 
for disease severity can be considered and made workable by HTAs, including QALY 
weightings according to proportional QALY shortfall. The adjusted QALY gain and 
corresponding ICERs of NPG versus G in pancreatic cancer show that the value of 
medicines for life-threatening ‘end-of-life’ conditions with a high relative shortfall 
can be reflected by an appropriate system of QALY weightings.
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objeCtives: The objective of the current analysis was to assess the cost-effective-
ness of lapatinib plus capecitabine versus capecitabine alone in human epidermal 
growth factor receptor-2-positive metastatic breast cancer patients from the third 
party payer perspective over a time horizon of ten years. Methods: A half cycle 
corrected Markov chain model comprising 3 health states (stable, progression and 
death) was developed to estimate the projected clinical and economic implications 
of Lapatinib. Transition probabilities were estimated based on the results from the 
EGF100151 clinical trial of Lapatinib. Health state utilities and major adverse events 
were obtained from published sources. Direct medical costs were obtained from the 
third party payer list. Costs (in 2013 EGP) and effects were discounted at 3.5% annu-
ally. One way sensitivity analyses were conducted. Results:  The economic evalu-
ation of lapatinib plus capecitabine as combination therapy resulted in additional 
cost of 1,597,796 EGP, with an incremental positive effect of 5.7 quality adjusted life 
years (QALY) or an incremental cost-effectiveness ratio (ICER) of 277,169 EGP/QALY 
gained. The overall survival of the two arms was found to have the greatest impact 
on the results. ConClusions: Compared with our willingness-to-pay threshold 
stated by world health organization for middle and lower income countries, the 
addition of lapatinib to capecitabine is not clearly cost-effective; and most likely to 
result in an ICER higher than the threshold limit.
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objeCtives: To evaluate health care resource utilization and costs among patients 
diagnosed with breast cancer in the Medicaid program. Methods: Patients diag-
nosed with breast cancer (International Classification of Disease, 9thRevision, 
Clinical Modification [ICD-9-CM] diagnosis code 174, 233.0, 238.3, 239.3) were identi-
fied using Medicaid data from January 1, 2008 through December 31, 2010. The initial 
diagnosis date was designated as the index date. Patients without breast cancer 
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ratio (ICUR) ranged from 11,921 to 17,215 CNY (1889 to 2728 US dollars, 2012) per 
QALY saved. All of the ICURs were much less than China’s GDP per capita (6247 US 
dollars, 2012). ConClusions: VIA screening at different intervals were all very cost-
effective options for 35-59 years old women in rural China. It is also noted that the 
cost-effective manner of aselected strategy largely depends on the local economic 
status and the performance of such organized program.
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objeCtives: This study aims to estimate incremental cost and utility of Home 
Parenteral Nutrition (HPN) in a heterogeneous group of cancer patients from the 
French public purchaser perspective, as compared with the same patients receiving 
no HPN. Methods: Two economic models, from public French perspective, were 
defined: a 28 day cost-utility model and a lifetime state transition model; both 
models were based on ecological data from an extensive literature search. Four 
health states were used in the second model: Home, two hospitalization states 
and death. Transition to death state was based on survival analysis obtained from 
published summary statistics from two different studies. Functional Assessment 
Cancer Therapy-general (FACT-g) scores, reported in a recently published French 
observational study, were used to compute utility weights in the intervention group 
by applying relevant published algorithms. In the control groups, they were com-
puted by decrementing the baseline utility weight of the intervention group. All 
costs: nutrition costs, resources consumption costs, complication costs and hospi-
talization costs were adapted from published French studies. Both Deterministic 
and Probabilistic Sensitivity Analyses were performed to test uncertainty. Results: 
The cost-utility ratio of HPN is estimated in 508,059 and 182,584 Euro per QALY gain, 
in the 28 day cost-utility model and the lifetime state transition model, respectively. 
DSA showed that survival in the control group and cost of the nutrition were the 
most influential parameters on the cost-utility ratio in both models. The probability 
for cost-effectiveness, considering a willingness to pay (WTP) 87,000 Euro (3XGDP 
per capita in France) for a QALY, was below 1% in both models. ConClusions: 
Final judgment on HPN cost-effectiveness is difficult, even if it seems to be not cost-
effective according to standard WTP. The high cost-utility ratio, which declines with 
increasing survival benefits, should urge clinicians and policy makers to control the 
sources of ineffectiveness.
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objeCtives: Irinotecan is an anti-cancer agent that is used for the treatment of 
metastatic colorectal cancer. Although it prolongs survival, it can cause severe toxic-
ity (e.g. diarrhea and neutropenia) in patients who carry the UGT1A1*28 allele. This 
study evaluates the cost-effectiveness of UGT1A1 genotyping prior to irinotecan-
based chemotherapy from the perspective of the German statutory health insur-
ance. Methods: We develop a decision-analytic Markov model to analyze costs 
and QALYs during a time horizon of six months (two-week cycles). No testing was 
compared to (1) change of chemotherapy to an irinotecan-free regimen, (2) dose 
reduction of irinotecan-based chemotherapy and (3) administration of a prophy-
lactic G-CSF growth factor for patients with a UGT1A1*28 variant. Probability, utility 
and cost parameters used in this study were extracted from published literature. 
Uncertainty was assessed by deterministic and probabilistic sensitivity analy-
ses. Results: Strategy (2) was the cheapest strategy associated with costs of about 
€ 12,600 and effects of approx. 0.32 QALYs. All other three strategies were absolutely 
dominated. Compared to no testing, strategy (2) resulted in only marginal increases 
of QALYs (0.0003) but reduced costs by about € 1,500 per patient. Strategy (1) resulted 
in smaller health gains (0.0002 QALYs) and smaller cost savings (about € 60). Strategy 
(3) yielded approximately the same QALY gains as strategy (2) but at higher costs. In 
the probabilistic analysis, strategy (2) was the optimal strategy in 52% of simulations 
at a threshold of € 50,000 per QALY. Uncertainty for this strategy originated primarily 
from the utility weights and the costs of chemotherapy. ConClusions: Our analy-
sis suggests that UGT1A1 genotyping and subsequent reduction of irinotecan-based 
chemotherapy has a substantial cost-saving potential. Due to the promising results, 
further research, for example in the form of a managed entry agreement would be 
desirable to validate these findings.
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objeCtives: Mutations in BRCA1 and BRCA2 are associated with an increased risk 
of breast and ovarian cancer. If a mutation is detected in women with ovarian 
cancer their unaffected relatives can potentially undergo gene testing and cancer 
risk-reducing surgery. Current UK practice is for any such relative to have access 
to testing. Guidelines also recommend that gene testing should be offered to indi-
viduals with BRCA mutation carrier probability of ≥ 10%, although this is not rou-
tinely implemented. In particular, many eligible women with ovarian cancer are not 
offered BRCA testing. Our aim is to evaluate the long-term cost-effectiveness in the 
UK of providing BRCA testing to women with ovarian cancer and to the unaffected 
female first-degree relatives of those with BRCA mutations. Methods: A Markov 
model with a lifetime horizon was developed to reflect the clinical and economic 
1IMS Health, London, UK, 2Bristol-Myers Squibb, Rueil Malmasion, France, 3Bristol-Myers Squibb, 
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objeCtives: Ipilimumab was the first compound to substantially prolong survival 
in advanced melanoma. Evaluate the cost-effectiveness of ipilimumab in untreated 
advanced melanoma compared to dacarbazine and vemurafenib from a Swedish 
national payer perspective (TLV/NLT). Methods: A three-state Markov model with 
stable disease, progression and death was developed, estimating costs and ben-
efits over a lifetime horizon. Given a lack of head-to-head data and a connected 
evidence network to allow for a robust NMA, the comparison used two sources of 
data unadjusted for study characteristics. Ipilimumab survival data were based 
on a pooled sample of treatment-naïve patients from clinical trials (n= 78) and 
real-world settings (n= 181), the clinical data package used for EMA submission. 
Parametric extrapolation methods were applied to dacarbazine data from CA184-
024. Mixture modelling was used to extrapolate vemurafenib data from BRIM-III. 
Resource use was taken from a survey of Swedish oncologists (n= 5). EORTC-8D 
utility data from an untreated population were used because they match the popula-
tion of interest. Costs were obtained from official Swedish price lists. Survival and 
utility assumptions were varied in scenario analyses. Results: Ipilimumab was 
associated with a 0.93 QALY gain and an ICER of SEK782,000 (€ 84,000) versus dacar-
bazine. Ipilimumab dominated vemurafenib with a 0.76 QALY gain and a SEK109,000 
(€ 15,000) cost-saving. The unadjusted comparison was the most conservative among 
alternative methods of clinical comparisons explored. The ICER versus dacarbazine 
was SEK521,000 (€ 56,000) using a published survival algorithm (7) and SEK532,000 
(€ 57,000) using a covariate-adjusted survival regression based on the 78-patient 
dataset. A real-world scenario using the patient shares of dacarbazine and vemu-
rafenib was also deemed cost-effective. ConClusions: As in the previously treated 
setting, ipilimumab produces large (> 0.5 year) survival and quality-adjusted sur-
vival gains relative to current treatments. TLV/ NLT considered ipilimumab a cost-
effective treatment for advanced melanoma based on these results.
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objeCtives: Trastuzumab, a targeted therapy, has been widely used in treatment 
of HER2-positive breast cancer because of its proved effectiveness and safety by 
many studies but its economic impact with low-income countries like Viet Nam has 
not been assessed yet. The aim of this study is to evaluate the cost-effectiveness 
of trastuzumab in combination of standard therapy versus standard therapy in 
treatment of metastatic HER2-positive breast cancer. Methods: A Markov model 
was developed with 3 states (stable disease, progressive disease and death) to simu-
late a hypothetical cohort of 1,000 metastatic HER2-positive breast cancer women 
of an average age of 53 year old with the same entry criteria as in the M77001 
study group. Chemotherapy with ACD regimen (Doxorubicin, Cyclophosphamide, 
Docetaxel) was compared with ACD regimen plus trastuzumab. The cycle length of 
model was 1 month and time horizon was lifetime. Both cost and Quality-adjusted 
life-years (QALYs) were discounted annually with 3% discount rate. Probabilistic 
sensitivity analysis was also conducted. Results: Combination of trastuzumab 
and standard therapy compared with standard therapy in treatment of metastatic 
HER2-positive breast cancer resulted in addition of 170.9 million VND (658,8 vs 487,9 
million VND) and 0.81 QALY (1.77 vs 0.96). The incremental cost-effectiveness ratio 
resulted in VND 208,736,442.49/QALY, which was less than willing to Pay (WTP) of 
VietNam in 2013 (VND 253,503,360.00). Therefore, using trastuzumab in treatment 
of metastatic HER2-positive breast cancer women has been considered to be cost-
effective. Sensitivity analyisis showed that the most affecting factors on the cost-
utility of trastuzumab are trastuzumab’s price and patient’s weight. ConClusions: 
Trastuzumab in combination of standard therapy is cost-effective in treatment of 
metastatic HER2-positive breast cancer women in Vietnam. Trastuzumab’s price 
and patient’s weight are the most affecting factors on the cost-effectiveness of 
trastuzumab.
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objeCtives: Chinese government initiated a nation-wide cervical screening pro-
gram, covering 10 million rural women in 221 counties all over the country. The 
objectives of the present study were to compare costs, health outcomes, and cost-
effectiveness of visual inspection with acetic acid (VIA) screening strategies in rural 
China, and to identify optimal screening intervals for policy makers. Methods: 
Markov simulation model was developed to synthesize the evidence of screening 
and treatment practices in rural China, and applied to predict the long-term costs 
and effectiveness for hypothetical cohorts over 20 years of screening. Model was 
validated by calibrating prediction with observation data on age-specific cervical 
cancer mortality and incidence in China. Costs were considered from a societal 
perspective while health effects were mainly expressed as quality-adjusted life 
years (QALY). Both cost and utility were collected on-site and discounted at 5% 
per year. Results: All completing alternatives showed certain benefits due to 
the decreased number of women developing cervical cancer. A trend for shorter 
screening intervals to have greater benefit was found. Under different screening 
intervals, mortality and incidence were expected to be reduced by 6.67-31.74% and 
5.12-23.60%, respectively. Comparing to no screening (status quo), ten-year VIA 
screening was identified as the most cost-effective option, followed by VIA screen-
ing every five-, three- and one year, with corresponding incremental cost-utility 
